SOC/Preferred term (N = 51) (N = 50) (N = 51) (N = 52) (N = 153) (MedDRA Version 18.1) Total patients* reporting one or 0 5 (9.8) 2 (4.0) 3 (5.9) 5 (3.3) more event† Musculoskeletal and connective 0 0 1 (2.0) 1 (2.0) 2 (1.3) tissue disorders Arthralgia 0 1 (2.0) 0 0 1 (0.7) Tendonitis 0 0 1 (2.0) 0 1 (0.7) Eye disorders 1 (2.0) 0 1 (2.0) 0 1 (0.7) Iridocyclitis 1 (2.0) 0 0 0 0 Keratitis 0 0 1 (2.0) 0 1 (0.7) Investigations 0 1 (2.0) 0 0 1 (0.7) Blood creatinine increased 0 1 (2.0) 0 0 1 (0.7) Vascular disorders 0 0 1 (2.0) 0 1 (0.7) Hypertension 0 0 1 (2.0) 0 1 (0.7) Skin and subcutaneous tissue 0 0 0 0 3 (5.9) disorders Atopic dermatitis 2 (3.9) 0 0 0 0 Eczema 1 (2.0) 0 0 0 0 Table E6. Contd Tralokinumab Placebo 45 mg 150 mg 300 mg Total
SOC/Preferred term (MedDRA Version 18.1) (N = 51) (N = 50) (N = 51) (N = 52) (N = 153) Total patients* reporting one or more event† 5 (9.8) 2 (4.0) 3 (5.9) 0 5 (3.3) Musculoskeletal and connective tissue disorders 0 1 (2.0) 1 (2.0) 0 2 (1.3) Arthralgia 0 1 (2.0) 0 0 1 (0.7) Tendonitis 0 0 1 (2.0) 0 1 (0.7) Eye disorders 1 (2.0) 0 1 (2.0) 0 1 (0.7) Iridocyclitis 1 (2.0) 0 0 0 0 Keratitis 0 0 1 (2.0) 0 1 (0.7) Investigations 0 1 (2.0) 0 0 1 (0.7) Blood creatinine increased 0 1 (2.0) 0 0 1 (0.7) Vascular disorders 0 0 1 (2.0) 0 1 (0.7) Hypertension 0 0 1 (2.0) 0 1 (0.7) Skin and subcutaneous tissue disorders 3 (5.9) 0 0 0 0 Atopic dermatitis 2 (3.9) 0 0 0 0 Eczema 1 (2.0) 0 0 0 0 Table E6. Contd Placebo Tralokinumab 45 mg 150 mg 300 mg Total
1-s2.0-S0091674918308509-mmc1.docx